ALL AIDSLINE ASK THE DOC CONFERENCES --5th IAS HIV Pathog & Treat --4th IAS HIV Pathog & Treat --3rd IAS HIV Pathog & Treat --2nd IAS HIV Pathog & Treat --1st IAS HIV Pathog & Treat -Intl AIDS Conferences --17th Int Conf AIDS: Toronto (2006) --16th Int Conf AIDS: Toronto (2006) --15th Int Conf AIDS: Bangkok (2004) --14th Int Conf AIDS: Barcelona (2002) --13th Int Conf AIDS: Durban (2000) --12th Int Conf AIDS: Geneva (1998) --11th Int Conf AIDS: Vancouver --10th Int Conf AIDS: Yokohoma --9th Int Conf AIDS: Berlin --8th Int Conf AIDS: Amsterdam --7th Int Conf AIDS: Florence --6th Int Conf AIDS: San Franciso --5th Int Conf AIDS: Montreal --4th Int Conf AIDS: Stockholm --3rd Int Conf AIDS: Washington --2nd Int Conf AIDS: Paris --1st Int Conf AIDS: Atlanta --9th Intl Cong. Drug Therapy: Glasgow 2008 --8th Intl Cong. Drug Therapy: Glasgow 2006 --7th Intl Cong. Drug Therapy: Glasgow 2004 --6th Intl Cong. Drug Therapy: Glasgow 2002 --5th Intl Cong Drug Therapy: Glasgow 2000 --3rd Intl Cong Drug Therapy: Glasgow 1996 --2nd Intl Cong Drug Therapy: Glasgow 1994 --10th Lipo: London, UK --9th Lipo: Sydney, Australia --8th Lipo: San Francisco --7th Lipo: Dublin, Ireland --6th Lipo: Washington, DC --5th Lipo: Paris, France --4th Lipo: San Diego --3rd Lipo: Athens, Greece --2nd Lipo: Toronto, Canada --1st Lipo: San Diego --15th Conf Retroviruses Opportunistic Infect --14th Conf Retroviruses Opportunistic Infect --13th Conf Retroviruses Opportunistic Infect --12th Conf Retroviruses Opportunistic Infect --11th Conf Retroviruses Opportunistic Infect --10th Conf Retroviruses Opportunistic Infect --9th Conf Retroviruses Opportunistic Infect --8th Conf Retroviruses Opportunistic Infect --7th Conf Retroviruses Opportunistic Infect --6th Conf Retroviruses Opportunistic Infect --5th Conf Retroviruses Opportunistic Infect --4th Conf Retroviruses Opportunistic Infect --3rd Conf Retroviruses Opportunistic Infect --2nd Conf Retroviruses Opportunistic Infect --1st Conf Retroviruses Opportunistic Infect --2005 Natl HIV Prev Conf --2003 Natl HIV Prev Conf --1999 Natl HIV Prev Conf --18th Intl Wkshop HIV Drug Resistance --17th Intl Wkshop HIV Drug Resistance --16th Intl Wkshop HIV Drug Resistance --15th Intl Wkshop HIV Drug Resistance --14th Intl Wkshop HIV Drug Resistance --13th Intl Wkshop HIV Drug Resistance --12th Intl Wkshop HIV Drug Resistance --11th Intl Wkshop HIV Drug Resistance --3rd Intl Wkshop HIV Drug Resistance --5th Intl Wkshop on HIV Drug Resistance & Treatment Strategies --4th Intl Wkshop on HIV Drug Resistance & Treatment Strategies --1st Intl Wkshop on HIV Drug Resistance & Treatment Strategies --15th British HIV Ass'n Conf 2009 --14th British HIV Ass'n Conf 2008 --13th British HIV Ass'n Conf 2007 --12th British HIV Ass'n Conf 2006 --11th British HIV Ass'n Conf 2005 --10th British HIV Ass'n Conf 2004 -- 9th British HIV Ass'n Conf 2003 -- 8th British HIV Ass'n Conf 2002 -- 7th British HIV Ass'n Conf 2001 --9th European AIDS Conf. --8th European AIDS Conf. FACT SHEETS --AIDS Treatment Data Network LAW NEWS SERVICES --AIDS Daily Summary --Agence France-Presse --Asia Times --Associated Press --Bay Area Reporter --BBC On-Line --Bangkok Post --Business Wire --CATIE --Chicago Tribune --FDA News --Inter Press Service --Integrated Regional Information Network --Los Angeles Times --Mail & Guardian --Miami Herald --Newsday --New Vision --New York Times --OC Weekly --PRNewswire --Reuters --San Francisco Chronicle --San Francisco Examiner --Sunday Times --UNAIDS --United Press International --Voice of America --Wall Street Journal --Washington Blade PUBLICATIONS --ACRIA --AIDS Treatment News --AIDS Weekly Plus --amfAR --Being Alive --BETA --BMC AIDS Res Therapy --CATIE --Emerging Infectious Diseases --Gay Men's Health Crisis --HIV Education Project --HIV Treatment Bulletin --IAPAC --IAVI --MMWR --Project Inform PLOS --PLOS Biology --PLOS Medicine --PLOS One --PLOS Pathogens --RITA --Treatment Action Group --Women Alive TOPICS Your Search for AIDS vaccine evaluation group or AVEG matched 144 Documents (Page 1 of 5). Results Indexed by relevance.
1.	Ribi Science Update: Ribi's MPL in Liposomes Superior as AIDS Vaccine Adjuvant, According to Preliminary Comparative Human Clinical Study Data (70%) Abstract: AEGIS, AIDS Daily Summary, HIV, AIDS, HIV infection, opportunistic infections. var gaJsHost = (https: = document.location.protocol) ? "https:ssl. : "http:www. document.write(unescape(3Cscript src= + gaJsHost + "google-analytics.com/ga.js' type=text/javascript'3E%3C/script%3E"ion" CONTENT=Data from a ... http://www.aegis.org/news/ads/1994/ad941929.html File Name: ad941929.html, Size: 10KB, Last Modified: Sunday, January 04, 2009 at 6:49:07 PM
2.	Future planning for HIV vaccine evaluation of Thai AIDS vaccine evaluation group (TAVEG) in Thailand. (70%) Abstract: After WHO announced in 1991 that four member states ( Brazil , Rwanda , Thailand and Uganda ) would be supported as HIV-1 vaccine testing sites, Thailand had agreed to parti ... http://www.aegis.org/aidsline/1998/dec/m98c3331.html File Name: m98c3331.html, Size: 10KB, Last Modified: Tuesday, December 29, 1998 at 6:29:23 AM
3.	AEGiS-12IAC: Future planning for HIV vaccine evaluation of Thai AIDS vaccine evaluation group (TAVEG) in Thailand. (70%) Abstract: After WHO announced in 1991 that four member states ( Brazil , Rwanda , Thailand and Uganda ) would be supported as HIV-1 vaccine testing sites, Thailand had agreed to participate in this very important scientific study, which based the ground that infrastructures for vac ... http://www.aegis.org/conferences/iac/1998/33222.html File Name: 33222.html, Size: 7KB, Last Modified: Sunday, June 28, 1998 at 8:12:04 PM
4.	Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. (70%) Abstract: The NIAID-sponsored AIDS Vaccine Evaluation Group was established in 1988 to perform phase I/II clinical trials with candidate preventive HIV-1 vaccines. This report includes safety data from 1398 HIV-negative, healthy volunteers who were enrolled into 25 phase I and 1 phase H multicentered, randomized, double-blind s ... http://www.aegis.org/aidsline/1998/jan/m9811038.html File Name: m9811038.html, Size: 10KB, Last Modified: Thursday, January 29, 1998 at 6:29:23 AM
5.	Clinical evaluation of experimental AIDS vaccines. (70%) Abstract: The process of conducting clinical trials of AIDS vaccines poses significant scientific and logistical challenges including strategies for recruitment of volunteers, confidentiality, vaccine induced seroconversion, and other difficult ethical dilemmas. In order to accelerate the development of a safe and effective AID ... http://www.aegis.org/aidsline/1990/sep/m9093421.html File Name: m9093421.html, Size: 9KB, Last Modified: Friday, September 28, 1990 at 8:12:04 PM
6.	AEGiS-05IAC: Clinical evaluation of experimental AIDS vaccines. (70%) Abstract: The process of conducting clinical trials of AIDS vaccines poses significant scientific and logistical challenges including strategies for recruitment of volunteers, confidentiality, vaccine induced seroconversion, and other difficult ethical dilemmas. In order to accelerate the development of a safe and effective AIDS ... http://www.aegis.org/conferences/iac/1989/mcp3.html File Name: mcp3.html, Size: 6KB, Last Modified: Sunday, June 04, 1989 at 7:12:04 PM
7.	AEGiS-Natl HIV Prev Conf 1999 [293]: Rates and determinants of positive HIV screening test results in uninfected participants in phase I/II trials of candidate HIV-1 vaccines. (35%) Abstract: The AIDS Vaccine Evaluation Group has carried out over 30 phase I/II trials in which 2750 uninfected volunteers have been enrolled using over 20 different vaccine candidates. Many vaccine approaches have induced antibodies in recipients that can be detected by commercially available HIV test kits ... http://www.aegis.org/conferences/nhivpc/1999/293.html File Name: 293.html, Size: 8KB, Last Modified: Saturday, January 10, 2009 at 12:18:53 AM
8.	(AW) Conference Coverage (12th World AIDS): Avipox AIDS Vaccine Elicits Durable Anti-HIV CTLs (35%) Abstract: More than half of the volunteers who received a candidate AIDS vaccine developed durable, HIV specific cytotoxic T-lymphocyte (CTL) responses. The vaccine is a canarypox virus engineered to express HIV genes. The virus is capable only of a single round of expression in human cells and has proven safe in earlier human t ... http://www.aegis.org/pubs/aidswkly/1998/aw980806.html File Name: aw980806.html, Size: 8KB, Last Modified: Monday, January 05, 2009 at 10:03:58 PM
9.	AEGiS-SFE: 2-pronged AIDS vaccine developed; Trial on gay men to start in April (35%) Abstract: WASHINGTON - A logjam has broken in AIDS vaccine research, with the results of a new trial showing that a new two-in-one product is safe and able to elicit two important types of immune response in human volunteers. One of the biggest challenges to AIDS vaccine work is that everything designed so far has triggered one ... http://www.aegis.org/news/sfe/1997/se970111.html File Name: se970111.html, Size: 8KB, Last Modified: Tuesday, March 06, 2007 at 6:23:25 PM
10.	A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. (35%) Abstract: Several immunogens induce HIV-specific neutralization and in vitro lymphoproliferation in adults at low HIV-1 risk, but responses in persons at high HIV-1 risk are not known. We performed a multicenter, double-blinded, adjuvant-controlled trial with two gp120 vaccines in 296 HIV-1-uninfected volunteers, including 176 ... http://www.aegis.org/aidsline/2000/sep/a0090516.html File Name: a0090516.html, Size: 10KB, Last Modified: Thursday, September 28, 2000 at 8:12:04 PM
11.	Rates and determinants of positive HIV screening test results in uninfected participants in phase I/II trials of candidate HIV-1 vaccines. (35%) Abstract: BACKGROUND/OBJECTIVES: The AIDS Vaccine Evaluation Group has carried out over 30 phase I/II trials in which 2750 uninfected volunteers have been enrolled using over 20 different vaccine candidates. Many vaccine approaches have induced antibodies in recipients that can be detected by commercially available HIV test kit ... http://www.aegis.org/aidsline/2000/may/a0051333.html File Name: a0051333.html, Size: 7KB, Last Modified: Sunday, May 28, 2000 at 8:12:04 PM
12.	AIDS preclinical vaccine development: biennial survey of HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. (35%) Abstract: ... http://www.aegis.org/aidsline/2000/feb/a0020329.html File Name: a0020329.html, Size: 7KB, Last Modified: Monday, February 28, 2000 at 8:12:04 PM
13.	AEGiS-07CROI: Mucosal antibody responses in HIV-infected individuals: antibody-secreting cells in peripheral blood. (35%) Abstract: Further studies are required to correlate the numbers, isotype and persistence of ASC generated in peripheral blood following HIV-infection with the route of transmission. ... http://www.aegis.org/conferences/croi/2000/110.html File Name: 110.html, Size: 5KB, Last Modified: Sunday, January 30, 2000 at 8:12:04 PM
14.	MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. (35%) Abstract: The ability of antibody induced by MN and IIIB recombinant gp120 (rgp120) human immunodeficiency virus type 1 (HIV-1) vaccines to bind to oligomeric native HIV-1 envelope glycoproteins of primary isolates of HIV-1 was measured by flow cytometric indirect immunofluorescence assay (FIFA) in 25 uninfected, healthy adults ... http://www.aegis.org/aidsline/1999/nov/a99b1081.html File Name: a99b1081.html, Size: 10KB, Last Modified: Sunday, November 28, 1999 at 8:12:04 PM
15.	Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. (35%) Abstract: OBJECTIVE: To determine the ability of live attenuated canarypox virus expressing HIV antigens to induce CD8+ cytotoxic T-cell responses and to prime for neutralizing antibody responses to boosting with purified recombinant gp120 subunit vaccine. DESIGN: A prospective, double-blind, randomized, immunogenicity and safe ... http://www.aegis.org/aidsline/1999/sep/a9990745.html File Name: a9990745.html, Size: 11KB, Last Modified: Tuesday, September 28, 1999 at 8:12:04 PM
16.	HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. (35%) Abstract: We evaluated prime-boost immunization with two recombinant envelope glycoprotein subunit vaccines (HIV-1MN recombinant gp160 vaccine in alum adjuvant [MN rgp160] and HIV-1MN recombinant gp120 vaccine in alum adjuvant [MN rgp120]) for safety and immunogenicity in healthy, HIV-1-uninfected adults. The rationale was to c ... http://www.aegis.org/aidsline/1999/jun/a9960255.html File Name: a9960255.html, Size: 11KB, Last Modified: Monday, June 28, 1999 at 8:12:04 PM
17.	CD8+ CTL induced in AIDS vaccine evaluation group phase I trials using canarypox vectors (ALVAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost. (35%) Abstract: OBJECTIVES: The use of live canarypox vectors provides a safe method for eliciting CTL which are desirable for developing an effective HIV vaccine strategy. We will present the frequency of CTL induced by canarypox vectors encoding gp160 (vCP125), the gp120 and gp41 TM portion of env, gag, and protease (vCP205), or th ... http://www.aegis.org/aidsline/1998/dec/m98c4674.html File Name: m98c4674.html, Size: 11KB, Last Modified: Tuesday, December 29, 1998 at 6:29:23 AM
18.	Frequency and duration of HIV-1 specific cytolytic reactivities elicited in response to candidate AIDS vaccines. (35%) Abstract: As Phase I/II clinical testing of AIDS vaccine candidates progresses, we have begun to better understand the character of the immune reactivities that can be elicited. We report here on antibody-dependent cellular cytotoxicity (ADCC) and CD8+ cytotoxic T-lymphocyte (CTL) responses induced in the context of two recent ... http://www.aegis.org/aidsline/1998/dec/m98c0288.html File Name: m98c0288.html, Size: 10KB, Last Modified: Tuesday, December 29, 1998 at 6:29:23 AM
19.	Interactions of secretory IgA with HIV-1 gp120: potential pitfalls of anti-HIV ELISA using saliva. (35%) Abstract: BACKGROUND: Early in the AIDS epidemic, saliva was suggested as an alternative to blood for the detection of anti-HIV antibodies and diagnosis of HIV infection. A number of papers reported data which supported this notion, indicating the presence of HIV-specific antibodies in saliva of varying proportions of HIV-serop ... http://www.aegis.org/aidsline/1998/dec/m98c2668.html File Name: m98c2668.html, Size: 10KB, Last Modified: Tuesday, December 29, 1998 at 6:29:23 AM
20.	Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. (35%) Abstract: A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus HIV)-uninfected adults who were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 and 1 or ... http://www.aegis.org/aidsline/1998/aug/m9881089.html File Name: m9881089.html, Size: 10KB, Last Modified: Saturday, August 29, 1998 at 6:29:23 AM
21.	Three new AIDS vaccine trials begin testing novel concepts. (35%) Abstract: The AIDS Vaccine Evaluation Group (AVEG) has begun enrollment in three new clinical trials that are testing a novel route of immunization (AVEG 027), an innovative vaccine strategy (AVEG 028), and a new adjuvant, or vaccine booster (AVEG 033). AVEG 027 is studying an experimental vaccine being applied topically to spe ... http://www.aegis.org/aidsline/1998/aug/m9880178.html File Name: m9880178.html, Size: 8KB, Last Modified: Saturday, August 29, 1998 at 6:29:23 AM
22.	New Trials Initiated in Thailand and the U.S. (35%) Abstract: Trials for a clade E version of Chiron s gp120 vaccine have been started by the Royal Thai Army. The vaccine, which is based on primary isolates of HIV, is being tested alone and in conjunction with clade B versions; clade E HIV is predominant in Thailand , although clade B strains are found among some sub -populations ... http://www.aegis.org/news/ads/1998/ad981413.html File Name: ad981413.html, Size: 9KB, Last Modified: Wednesday, July 15, 1998 at 3:00:00 PM
23.	Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. (35%) Abstract: The safety and immunogenicity of HIV-1MN recombinant gp160 (MN rgp160) vaccine in healthy, uninfected volunteers was tested in a double-blind study with a factorial design. By random assignment, 20 volunteers received three 200 micrograms doses of MN rgp160 and four volunteers received placebo at days 0, 28, and 168 o ... http://www.aegis.org/aidsline/1998/jun/m9861278.html File Name: m9861278.html, Size: 9KB, Last Modified: Monday, June 29, 1998 at 6:29:23 AM
24.	AEGiS-12IAC: AVEG 031: phase I evaluation of a gag-pol facilitated DNA vaccine for HIV-1 prevention. (35%) Abstract: <p><b>OBJECTIVES:</b> To evaluate in HIV-1 uninfected human volunteers the safety, tolerability, and immunogenicity of a candidate gag-pol HIV-1 DNA vaccine. SIGNIFICANCE: DNA vaccines have immunogenicity properties similar to attenuated virus or live vector vaccination without their risks. DNA vaccines are therefore ... http://www.aegis.org/conferences/iac/1998/33216.html File Name: 33216.html, Size: 7KB, Last Modified: Sunday, June 28, 1998 at 8:12:04 PM
25.	AEGiS-12IAC: CD8+ CTL induced in AIDS vaccine evaluation group phase I trials using canarypox vectors (ALVAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost. (35%) Abstract: <p><b>OBJECTIVES:</b> The use of live canarypox vectors provides a safe method for eliciting CTL which are desirable for developing an effective HIV vaccine strategy. We will present the frequency of CTL induced by canarypox vectors encoding gp160 (vCP125), the gp120 and gp41 TM portion of env, gag, and protease (vCP ... http://www.aegis.org/conferences/iac/1998/49521192.html File Name: 49521192.html, Size: 7KB, Last Modified: Sunday, June 28, 1998 at 8:12:04 PM
26.	AEGiS-12IAC: Interactions of secretory IgA with HIV-1 gp120: potential pitfalls of anti-HIV ELISA using saliva. (35%) Abstract: <p><b>BACKGROUND:</b> Early in the AIDS epidemic, saliva was suggested as an alternative to blood for the detection of anti-HIV antibodies and diagnosis of HIV infection. A number of papers reported data which supported this notion, indicating the presence of HIV-specific antibodies in saliva of varying proportions o ... http://www.aegis.org/conferences/iac/1998/16241101.html File Name: 16241101.html, Size: 7KB, Last Modified: Sunday, June 28, 1998 at 8:12:04 PM
27.	(NIH) Communities Honor HIV/AIDS Vaccine Volunteers (35%) Abstract: Community groups across the country have declared May 18 as the first HIV/AIDS Vaccine Awareness Day. ... http://www.aegis.org/news/nih/1998/ni980501.html File Name: ni980501.html, Size: 12KB, Last Modified: Sunday, June 14, 1998 at 12:00:00 AM
28.	Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. (35%) Abstract: ... http://www.aegis.org/aidsline/1998/may/m9851120.html File Name: m9851120.html, Size: 7KB, Last Modified: Friday, May 29, 1998 at 6:29:23 AM
29.	Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. (35%) Abstract: ... http://www.aegis.org/aidsline/1998/may/m9851121.html File Name: m9851121.html, Size: 7KB, Last Modified: Friday, May 29, 1998 at 6:29:23 AM
30.	Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation Group. (35%) Abstract: ... http://www.aegis.org/aidsline/1998/may/m9850916.html File Name: m9850916.html, Size: 6KB, Last Modified: Friday, May 29, 1998 at 6:29:23 AM
	1 2 3 4 5 Next
	AEGiS Search Engine. Status: The Index is up to date.